UNSPSC 51342703: Telaprevir

This classification denotes an antiviral agent with the molecular formula C36H53N7O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 655M5O3W0U. European Medicines Agency schedules telaprevir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB31651. The term TELAPREVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 20, no. 3, 2006, list 56. ). Most nations schedule telaprevir under HS 29339990 and SITC 51577.

As of Q4 2014, TELAPREVIR remains the US FDA Preferred Term for this commodity. Telaprevir bears US NLM identifiers UMLS ID C1876229 and NCI Concept Code C81603. SMILES: CCCC(C(=O)C(=O)NC1CC1)NC(=O)C2C3CCCC3CN2C(=O)C(C(C)(C)C)NC(=O)C(C4CCCCC4)NC(=O)C5=NC=CN=C5.

UNSPSC 51342703 Telaprevir is a Commodity code representing antiviral pharmaceutical products; however, the recent state and local solicitations tagged under this code do not align with telaprevir procurement. Instead, the opportunities posted reflect acquisitions of broader pharmaceutical inventory including antibiotic tablets, naloxone, and drug deactivation systems. State and local health departments and county public health agencies are the primary issuing bodies, seeking to stock emergency pharmaceuticals and harm-reduction supplies through competitive bidding processes. Solicitations are structured as fixed-fee contracts with multi-year terms and renewal options, often requiring quarterly or as-needed deliveries to centralized health facilities.

Activity under this code spans Florida and Illinois. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback pharmaceutical warehouse contract to Chartwell Rx LLC on August 28, 2026 (Solicitation 26482DPHPREPDB53392, IFB, closed award) for doxycycline and ciprofloxacin tablets under the MMCAP Infuse cooperative purchasing vehicle. Seminole County, Florida posted an IFB on June 30, 2026 (IFB60459723LAS, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the procurement included FEMA funding and required drug-free workplace and E-Verify compliance. The code shows minimal recent activity directly tied to telaprevir, suggesting low current demand or potential miscoding in state and local procurement systems when antiviral inventories are acquired.